Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
What's new in rosacea
Description
The presentation discusses recent advancements and alternatives in the treatment of rosacea, emphasizing that it is often overshadowed by acne-related discussions. Tetracyclines are highlighted for their anti-inflammatory properties rather than their antibacterial effects in treating rosacea. However, concerns about antibiotic resistance arise, prompting exploration of lower-dose alternatives like modified-release doxycycline and new formulations of minocycline with anti-inflammatory effects and minimal risk of antibiotic resistance. The efficacy of a new microencapsulated benzoyl peroxide formulation is noted for its slow release and significant reduction in inflammatory lesions, suggesting its potential utility in rosacea management. Furthermore, there are findings on how benzoyl peroxide may normalize the skin microbiome and reduce specific bacteria associated with rosacea. The role of mast cells and various treatment options, including hydroxychloroquine and botulinum toxin, are explored for their potential to alleviate rosacea symptoms through various mechanisms, including mast cell stabilization and neurovascular regulation. The overall message is an emphasis on evolving understanding and novel interventions for effectively managing rosacea.
View moreConclusions
- Modified release doxycycline provides effective anti-inflammatory treatment for rosacea without the systemic absorption issues of traditional antibiotics.
- Low-dose extended-release minocycline shows significant efficacy in reducing inflammatory lesions compared to placebo and traditional doxycycline.
- Recent studies indicate that minocycline does not develop antibiotic resistance, suggesting its safety for long-term use in treating rosacea.
- Microencapsulated benzoyl peroxide 5% demonstrates excellent tolerability and anti-inflammatory properties, leading to a normalization of the skin microbiome in rosacea patients.
- Botulinum toxin type A can significantly reduce erythema in rosacea by blocking mast cell degranulation and lowering levels of inflammatory mediators.
- Mast cell activity plays a crucial role in the pathophysiology of rosacea, influencing both inflammation and neurovascular responses.
- Hydroxychloroquine is a viable alternative treatment that proves effective without the adverse effects associated with traditional oral antibiotics for rosacea.
- Cazalis J, Bodet C, et al. J Periodontol. 2008;79:1762-1768.
- Ueyama Y, Misaki M, et al. Br J Oral Maxillofac Surg. 1994;32:96-99.
- Pruzanski W, Stefanski E, et al. J Rheumatol. 1998;25:1807-1812.
- Hoyt JC, Ballering J, et al. J Immunol. 2006;176:567-572.
- Akamatsu H, Asada M, et al. Acta Derm Venereol. 1992;72:178-179.
- Dan L, Shi-long Y, et al. Curr Eye Res. 2008;33:653-660.
- Fowler, J. Expert Rev Dermatol. 2007; 2(5):523-531.
- PubChem. Accessed July 1, 2024. https://pubchem.ncbi.nlm.nih.gov/compound/Minocycline.
- Bhatia N, Sidgiddi S. Poster AAD Annual Meeting March 8-12, San Diego, CA.
- Marchitto M, Chien A. Dermatol Ther (Heidelb). 2021;11(5):1541-1549.
- Tu K-Y et al. Front Immunol 2024;15:1403798.
- Aroni K et al. Arch Derm Res. 2008;300(3):125-31.
- Muto Y et al. J Invest Dermatol. 2014;134(11):2728-36.
- Two AM et al. JAAD 2015;72(5):748-58.
- Ahn CS, Huang WW. Dermatol Clin 2018;36(2):81-6.